Fenge Li

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 5

Top Topics

Peritoneal Dialysis

Ejection Fraction

Top Venues

International journal of women's health

Clinics (Sao Paulo, Brazil)

Journal for immunotherapy of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Fenge Li, Yupeng Wang, Jin Yan, Huancheng Wu, Xueming Du, Weihong Feng, Xiaoqing Zhang, Yongming Xue, Huaqing Wang, Wenxin Liu
Autologous Tumor-Infiltrating Lymphocyte Mono-Therapy Can Rapidly Shrank Tumor in Asian Patient with Stage III/IV Cervical Cancer: Two Cases Report. International journal of women's health 16 (2024)
Fenge Li, Yupeng Wang, Jin Yan, Huancheng Wu, Xueming Du, Weihong Feng, Xiaoqing Zhang, Yongming Xue, Huaqing Wang, Wenxin Liu
Autologous Tumor-Infiltrating Lymphocyte Mono-Therapy Can Rapidly Shrank Tumor in Asian Patient with Stage III/IV Cervical Cancer: Two Cases Report. International journal of women's health 16 (2024)
Fenge Li, Ligang Deng, Kyle R Jackson, Amjad H Talukder, Arjun S Katailiha, Sherille D Bradley, Qingwei Zou, Caixia Chen, Chong Huo, Yulun Chiu, Matthew Stair, Weihong Feng, Aleksander Bagaev, Nikita Kotlov, Viktor Svekolkin, Ravshan Ataullakhanov, Natalia Miheecheva, Felix Frenkel, Yaling Wang, Minying Zhang, David Hawke, Ling Han, Shuo Zhou, Yan Zhang, Zhenglu Wang, William K Decker, Heather M Sonnemann, Jason Roszik, Marie-Andree Forget, Michael A Davies, Chantale Bernatchez, Cassian Yee, Roland Bassett, Patrick Hwu, Xueming Du, Gregory Lizée
Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. Journal for immunotherapy of cancer 9 (7) (2022)
Yimo Sun, Fenge Li, Heather Sonnemann, Kyle R Jackson, Amjad H Talukder, Arjun S Katailiha, Gregory Lizee
Evolution of CD8+ T Cell Receptor (TCR) Engineered Therapies for the Treatment of Cancer. Cells 10 (9) (2021)
Yan Lan, Shuo Zhou, Weihong Feng, Ying Qiao, Xueming Du, Fenge Li
Association of tumor mutation burden and epidermal growth factor receptor inhibitor history with survival in patients with metastatic stage III/IV non-small-cell lung cancer: A retrospective study. Clinics (Sao Paulo, Brazil) 76 (2021)